Resumen
Background: We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world’s largest international, standardized data sets concerning hospitalized patients. Methods: The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admission to an intensive care unit (ICU) and invasive mechanical ventilation (IMV). Results: Data were available for 689 572 patients with laboratory-confirmed (91.1%) or clinically diagnosed (8.9%) SARS-CoV-2 infection from 52 countries. Age [adjusted hazard ratio per 10 years 1.49 (95% CI 1.48, 1.49)] and male sex [1.23 (1.21, 1.24)] were associated with a higher risk of death. Rates of admission to an ICU and use of IMV increased with age up to age 60 years then dropped. Symptoms, co-morbidities and treatments varied by age and had varied associations with clinical outcomes. The case-fatality ratio varied by country partly due to differences in the clinical characteristics of recruited patients and was on average 21.5%. Conclusions: Age was the strongest determinant of risk of death, with a ~30-fold difference between the oldest and youngest groups; each of the co-morbidities included was associated with up to an almost 2-fold increase in risk. Smoking and obesity were also associated with a higher risk of death. The size of our international database and the standardized data collection method make this study a comprehensive international description of COVID-19 clinical features. Our findings may inform strategies that involve prioritization of patients hospitalized with COVID-19 who have a higher risk of death.
| Idioma original | Inglés |
|---|---|
| Páginas (desde-hasta) | 355-376 |
| Número de páginas | 22 |
| Publicación | International Journal of Epidemiology |
| Volumen | 52 |
| N.º | 2 |
| DOI | |
| Estado | Publicada - 1 abr. 2023 |
Nota bibliográfica
Publisher Copyright:© The Author(s) 2023. Published by Oxford University Press on behalf of the International Epidemiological Association.
Financiación
| Financiadores | Número del financiador |
|---|---|
| European Clinical Research Alliance on Infectious Diseases | |
| Sunnybrook Research Institute | |
| Seventh Framework Programme | |
| Ministerio de Ciencia | |
| Instituto de Salud Carlos III | |
| Institut national de la santé et de la recherche médicale | |
| Artificial Intelligence for Pandemics | |
| Italian Ministry of Health ‘Fondi Ricerca corrente | |
| Prince Charles Hospital Foundation | |
| South Eastern Norway Health Authority and the Research Council of Norway | |
| Groote Schuur Hospital Covid ICU Team | |
| COVID-19 Clinical Management team | |
| National Institute for Health Research Health Protection Research Unit | |
| University of Queensland | |
| Manipal Hospital Whitefield | |
| foundation Bevordering Onderzoek Franciscus | |
| University of Cape Town | |
| Firland Foundation | |
| Manchester Biomedical Research Centre | |
| University of Oxford | |
| HPRU | |
| Bill and Melinda Gates Foundation | OPP1209135 |
| Conselho Nacional de Desenvolvimento Científico e Tecnológico | 303953/2018–7 |
| Liverpool Experimental Cancer Medicine Centre | C18616/A25153 |
| Horizon 2020 Framework Programme | 965313, 101003589 |
| Public Health England | 200907 |
| Imperial College London | 200927 |
| National Institute for Health and Care Research | CO-CIN-01 |
| Wellcome Trust | 220757, 220757/Z/20/Z, 215091/Z/18/Z, 205228/Z/16/ Z, 205228 |
| Stiftungsfonds zur Förderung der Bekämpfung der Tuberkulose und anderer Lungenkrankheiten of the City of Vienna | APCOV22BGM |
| Biotechnology and Biological Sciences Research Council | BBS/E/RL/230002D |
| Australian Department of Health | 3273191 |
| Norges Forskningsråd | NIHR201385, 312780 |
| European Federation of Pharmaceutical Industries and Associations | NCT04262921 |
| Innovative Medicines Initiative | 115523 |
| NIHR Biomedical Research Centre at Imperial College London | IS-BRC-1215–20013 |
| Canadian Institutes of Health Research | OV2170359 |
| Ministère des Affaires Sociales et de la Santé | PHRC n 20–0424 |
| UK Research and Innovation | MC_PC_19059 |
| Health Research Board | CTN-2014–12 |
| Australian Research Council | CE170100009 |
| Medical Research Council | MR/V001671/1 |